Table 1. Baseline demographic characteristics, treatment protocols used and response to therapy (n = 94).
| Parameters | Statistics |
|---|---|
| Age (years) | Median: 33 Range: 14-70 |
| Male/Female | 48/46 |
| BCR-ABL Fusion transcript type | – |
| e1a2 | 66 (70%) |
| others | 28 (30%) |
| WBC count (per μL) | Median: 34,200 Range: 1400–477,000 |
| Blast percentage (%) | Median: 90 Range: 28–100 |
| Platelet count (per μL) | Median: 39,000 Range: 4000–413,000 |
| CD20 expression | – |
| Positive | 28 |
| Negative | 29 |
| Not available | 37 |
| Additional chromosomal abnormalities | 47 (50%) |
| Good risk | 9 (9.5%) |
| Poor risk | 20 (21.3%) |
| Others | 18 (19.1%) |
| CNS Staging [I/II/III/NA] | 71/3/4/16 |
| Treatment regimens | – |
| Hyper CVAD | 55 (58%) |
| Modified GMALL | 16 (17%) |
| BFM based protocol | 23 (25%) |
| End Induction marrow | – |
| Complete remission (CR) | 75 (80%) |
| No CR | 13 (14%) |
| Not available | 6 (6%) |
| Time from diagnosis to transplant (months) | Median: 6 Range: 3–14 months |
WBC: white blood cells; CD: cluster of differentiation; CNS: central nervous system; CVAD: cyclophosphamide, vincristine, doxorubicin (adriamycin), and dexamethasone; GMALL: German multicentre acute lymphoblastic leukemia; BFM: Berlin Frankfurt Munich.